2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: Initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Arthritis care & research

• Publication date

  2011-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/acr.20460PMID 21452260PMCID PMC3222233
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis

  2010cited by this paper
• EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

  2010cited by this paper
• EULAR (欧州リウマチ学会) 合成および疾患修飾性抗リウマチ生物学的製剤による関節リウマチ管理に関する推奨ガイドライン | 文献情報 | J-GLOBAL 科学技術総合リンクセンター

  2010cited by this paper
• Clinical Remission in Patients with Systemic Juvenile Idiopathic Arthritis Treated with Anti-Tumor Necrosis Factor Agents

  2009cited by this paper
• Anakinra for Systemic Juvenile Arthritis: The Rocky Mountain Experience

  2009cited by this paper
• Development and validation of a composite disease activity score for juvenile idiopathic arthritis.

  2009cited by this paper
• Adalimumab with or without Methotrexate in Juvenile Rheumatoid Arthritis

  2009influential reference
• Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study

  2009cited by this paper
• Monitoring Methotrexate Toxicity in Juvenile Idiopathic Arthritis

  2009cited by this paper
• Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register

  2008cited by this paper
• American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis.

  2008cited by this paper
• Measurement of biomarkers in juvenile idiopathic arthritis patients and their significant association with disease severity: a comparative study.

  2008cited by this paper
• Time to treatment as an important factor for the response to methotrexate in juvenile idiopathic arthritis

  2008cited by this paper
• Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry

  2008cited by this paper
• Factors Influencing the efficacy of intra-articular steroid injections in patients with juvenile idiopathic arthritis

  2008cited by this paper
• Development and validation of a preliminary definition of minimal disease activity in patients with juvenile idiopathic arthritis.

  2008cited by this paper
• Adalimumab with or without methotrexate in juvenile rheumatoid arthritis.

  2008cited by this paper
• Anti-Cyclic Citrullinated Peptide Antibodies in Patients with Juvenile Idiopathic Arthritis

  2008cited by this paper
• Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis.

  2008cited by this paper
• Optimal treatment of knee monarthritis in juvenile idiopathic arthritis: a decision analysis.

  2008cited by this paper
• Drug survival of the first and second course of anti-tumour necrosis factor agents in juvenile idiopathic arthritis

  2008cited by this paper
• Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial.

  2008cited by this paper
• The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis.

  2008cited by this paper
• Long-term outcome of juvenile idiopathic arthritis following a placebo-controlled trial: sustained benefits of early sulfasalazine treatment

  2007cited by this paper
• A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis.

  2007cited by this paper
• Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.

  2007cited by this paper
• Predictors of disease course and remission in systemic juvenile idiopathic arthritis: significance of early clinical and laboratory features.

  2006cited by this paper
• The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial.

  2006cited by this paper
• Cyclosporine A in juvenile idiopathic arthritis. Results of the PRCSG/PRINTO phase IV post marketing surveillance study.

  2006cited by this paper
• Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.

  2006cited by this paper
• Epidemiology of rheumatoid arthritis, juvenile idiopathic arthritis and gout in two regions of the Czech Republic in a descriptive population-based survey in 2002-2003.

  2006cited by this paper
• Benefit of intraarticular corticosteroid injection under fluoroscopic guidance for subtalar arthritis in juvenile idiopathic arthritis.

  2006cited by this paper
• Radiographic and clinical outcome in early juvenile rheumatoid arthritis and juvenile spondyloarthropathy: a 3-year prospective study.

  2006cited by this paper
• Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study.

  2006cited by this paper
• A multicenter study of patients with adult-onset Still’s disease compared with systemic juvenile idiopathic arthritis

  2006cited by this paper
• Long-term outcome and prognostic factors in enthesitis-related arthritis: a case-control study.

  2006cited by this paper
• A randomized, double-blind clinical trial of two doses of meloxicam compared with naproxen in children with juvenile idiopathic arthritis: short- and long-term efficacy and safety results.

  2005cited by this paper
• Anti-tumor necrosis factor alpha blockade in the treatment of juvenile spondylarthropathy.

  2005cited by this paper
• Anti–tumor necrosis factor α blockade in the treatment of juvenile spondylarthropathy

  2005cited by this paper
• Leflunomide or methotrexate for juvenile rheumatoid arthritis.

  2005cited by this paper
• Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists.

  2005cited by this paper
• Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade

  2005cited by this paper
• Low-dose methotrexate treatment for oligoarticular juvenile idiopathic arthritis nonresponsive to intra-articular corticosteroids

  2005cited by this paper
• Efficacy of repeated intravenous infusions of an anti-tumor necrosis factor alpha monoclonal antibody, infliximab, in persistently active, refractory juvenile idiopathic arthritis: results of an open-label prospective study.

  2005cited by this paper
• Use of infliximab in patients with systemic juvenile idiopathic arthritis refractory to etanercept.

  2005cited by this paper
• Juvenile chronic arthritis: Imaging of the knees and hips before and after intraarticular steroid injection

  2005cited by this paper
• Intra-articular steroids in pauciarticular juvenile chronic arthritis, type 1

  2005cited by this paper
• Etanercept treatment in patients with refractory systemic onset juvenile rheumatoid arthritis.

  2005cited by this paper
• Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate.

  2004cited by this paper
• Guidelines for blood test monitoring of methotrexate toxicity in juvenile idiopathic arthritis.

  2004cited by this paper
• Prolonged efficacy of etanercept in refractory enthesitis-related arthritis.

  2004cited by this paper
• A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate.

  2004cited by this paper
• Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis.

  2004cited by this paper
• Triamcinolone acetonide and hexacetonide intra-articular treatment of symmetrical joints in juvenile idiopathic arthritis: a double-blind trial.

  2004cited by this paper
• Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis.

  2004cited by this paper
• The role of subcutaneous administration of methotrexate in children with juvenile idiopathic arthritis who have failed oral methotrexate.

  2004cited by this paper
• International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001.

  2004cited by this paper
• Infliximab in two patients with juvenile ankylosing spondylitis

  2004cited by this paper
• International League of Associations for Rheumatology: International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001

  2004cited by this paper
• The German etanercept registry for treatment of juvenile idiopathic arthritis

  2004cited by this paper
• Comparison of the intraarticular effectiveness of triamcinolone hexacetonide and triamcinolone acetonide in treatment of juvenile rheumatoid arthritis.

  2004cited by this paper
• Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type.

  2003cited by this paper
• Prognostic factors for radiographic progression, radiographic damage, and disability in juvenile idiopathic arthritis.

  2003cited by this paper
• Prognostic factors in juvenile rheumatoid arthritis: a case-control study revealing early predictors and outcome after 14.9 years.

  2003cited by this paper
• Health status of patients with juvenile rheumatoid arthritis at 1 and 5 years after diagnosis.

  2003cited by this paper
• Comparison of intra-articular triamcinolone hexacetonide and triamcinolone acetonide in oligoarticular juvenile idiopathic arthritis.

  2003cited by this paper
• Radiologic features in juvenile idiopathic arthritis: a first step in the development of a standardized assessment method.

  2003cited by this paper
• The influence of patient characteristics, disease variables, and HLA alleles on the development of radiographically evident sacroiliitis in juvenile idiopathic arthritis.

  2002cited by this paper
• Hepatotoxicity in patients with juvenile idiopathic arthritis receiving longterm methotrexate therapy.

  2002cited by this paper
• Treatment of juvenile idiopathic arthritis with intra-articular triamcinolone hexacetonide: evaluation of clinical effectiveness correlated with circulating ANA and T gamma/delta + and B CD5+ lymphocyte populations of synovial fluid.

  2002cited by this paper
• Long-term outcome in patients with juvenile idiopathic arthritis.

  2002cited by this paper
• Long-term follow-up of 246 adults with juvenile idiopathic arthritis: functional outcome.

  2002cited by this paper
• The efficacy and safety of intraarticular corticosteroid therapy for coxitis in juvenile rheumatoid arthritis.

  2002cited by this paper
• The early pattern of joint involvement predicts disease progression in children with oligoarticular (pauciarticular) juvenile rheumatoid arthritis.

  2002cited by this paper
• The RAND/UCLA Appropriateness Method User's Manual

  2001influential reference
• Systemic onset juvenile chronic arthritis, polyarticular pattern and hip involvement as markers for a bad prognosis.

  2001cited by this paper
• Factors affecting the efficacy of intraarticular corticosteroid injection of knees in juvenile idiopathic arthritis.

  2001cited by this paper
• Efficacy and safety profile of cyclosporin A in the treatment of juvenile chronic (idiopathic) arthritis. Results of a 10-year prospective study.

  2001cited by this paper
• Juvenile chronic arthritis into adulthood: a long-term follow-up study.

  2000cited by this paper
• Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis.

  2000cited by this paper
• A subgroup-specific evaluation of the efficacy of intraarticular triamcinolone hexacetonide in juvenile chronic arthritis.

  2000cited by this paper
• Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group.

  2000cited by this paper
• Long-term outcome and prognosis in oligoarticular-onset juvenile idiopathic arthritis.

  2000cited by this paper
• Early predictors of poor functional outcome in systemic-onset juvenile rheumatoid arthritis: a multicenter cohort study.

  2000cited by this paper
• Intraarticular triamcinolone hexacetonide injection in children with chronic arthritis: a survey of clinical practice.

  1999cited by this paper
• Efficacy and safety of methotrexate therapy for juvenile rheumatoid arthritis.

  1999cited by this paper
• Prevention of leg length discrepancy in young children with pauciarticular juvenile rheumatoid arthritis by treatment with intraarticular steroids.

  1999cited by this paper
• Juvenile arthritis--who gets it, where and when? A review of current data on incidence and prevalence.

  1999cited by this paper
• Intraarticular corticosteroid injection in the management of children with chronic arthritis.

  1998cited by this paper
• Outcome and predictive factors in juvenile rheumatoid arthritis and juvenile spondyloarthropathy.

  1998cited by this paper
• Sulfasalazine in the treatment of juvenile chronic arthritis: a randomized, double-blind, placebo-controlled, multicenter study. Dutch Juvenile Chronic Arthritis Study Group.

  1998cited by this paper
• Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis.

  1998cited by this paper
• Juvenile chronic arthritis: diagnosis and management of tibio-talar and sub-talar disease.

  1997cited by this paper
• Long-term health outcomes and quality of life in American and Italian inception cohorts of patients with juvenile rheumatoid arthritis. II. Early predictors of outcome.

  1997cited by this paper
• Long-term health outcomes and quality of life in American and Italian inception cohorts of patients with juvenile rheumatoid arthritis. I. Outcome status.

  1997cited by this paper
• Juvenile chronic arthritis: diagnosis and management of tibio-talar and sub-talar disease.

  1997cited by this paper
• American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid‐induced osteoporosis

  1996cited by this paper
• 6-methylprednisolone 'mini-pulses': a new modality of glucocorticoid treatment in systemic onset juvenile chronic arthritis.

  1996cited by this paper
• The natural history of juvenile chronic arthritis: a population based cohort study. II. Outcome.

  1995cited by this paper
• The natural history of juvenile chronic arthritis: a population based cohort study. I. Onset and disease process.

  1995cited by this paper

• Pan American League of Associations for Rheumatology: Recommendations for the Treatment of Oligoarticular Juvenile Idiopathic Arthritis.

  2026cites this paper
• Prevalence and risk factors for acute kidney injury at the diagnosis of juvenile idiopathic arthritis in children and its long-term implications for kidney health.

  2026cites this paper
• Sex differences in PROMIS Pediatric Depressive Symptoms, Anxiety, and Psychological Stress among children and adolescents living with pediatric rheumatic diseases.

  2026cites this paper
• Renal involvement in different subtypes of children with juvenile idiopathic arthritis: results from a single-center cohort

  2026cites this paper
• PAFLAR guidelines for oligoarticular juvenile idiopathic arthritis

  2026influential citation
• Effect of exercise interventions on physical function, cardiorespiratory fitness, and health-related quality of life in patients with juvenile idiopathic arthritis: a meta-analysis of randomized controlled trials

  2026cites this paper
• Evaluation of ILAR and PRINTO classifications for juvenile idiopathic arthritis: oligoarticular JIA vs early-onset ANA-positive JIA

  2025cites this paper
• The Number of Affected Joints Is Still a Distinguishing Criterion for Classifying Patients With Juvenile Idiopathic Arthritis.

  2025cites this paper
• Juvenile Idiopathic Arthritis and Spondylarthritis

  2025cites this paper
• Frequency of Methotrexate Intolerance in Juvenile Idiopathic Arthritis Patients Using Methotrexate Intolerance Severity Score

  2025cites this paper
• Artritis idiopática juvenil poliarticular: Manifestaciones sistémicas y desafíos terapéuticos en paciente adolescente [Juvenile idiopathic polyarticular arthritis: Systemic manifestations and therapeutic challenges in adolescent patients]

  2025cites this paper
• Biologics promote catch-up growth in young Juvenile idiopathic arthritis patients with lower body height.

  2025cites this paper
• How treatment choices influence the onset and outcomes of uveitis in juvenile idiopathic arthritis: a retrospective cohort study

  2025cites this paper
• Cervical spine arthritis as initial manifestation in Juvenile Idiopathic Arthritis: a multicenter retrospective study

  2025cites this paper
• Treatment of refractory poly articular course juvenile idiopathic arthritis with tofacitinib: Extended experience from Bangladesh

  2025cites this paper
• Imaging techniques for evaluating temporomandibular joint involvement in juvenile idiopathic arthritis: a systematic review.

  2025cites this paper
• Factors that influence school attendance and participation in children and adolescents with juvenile idiopathic arthritis - a systematic review of the literature

  2025cites this paper
• Tumor necrosis factor (TNF) inhibitors for juvenile idiopathic arthritis.

  2025cites this paper
• Global research trends in biological therapy for ankylosing spondylitis: A comprehensive visualization and bibliometric study (2004–2023)

  2025cites this paper
• Clinical Features and Risk Factors for Early Bone Destruction in Enthesitis‐Related Arthritis: A Cohort Study

  2025cites this paper
• Juvenile arthritis damage index predicts poor response to biological treatment: A prospective cohort study

  2025cites this paper
• Safety and effectiveness of intravenous abatacept for polyarticular-course juvenile idiopathic arthritis: An all-case postmarketing surveillance study

  2025cites this paper
• Pediatric Society of the African League Against Rheumatism juvenile idiopathic arthritis recommendations for enthesitis-related arthritis and juvenile psoriatic arthritis

  2025influential citation
• CASE REPORT : JUVENILE IDIOPATHIC ARTHRITIS

  2025cites this paper
• The long-term follow up of patients with oligoarticular juvenile idiopathic arthritis: a single center experience.

  2025cites this paper
• Bibliometric Analysis of Juvenile Idiopathic Arthritis From 2012 to 2023

  2025cites this paper
• Optimizing laboratory medication safety monitoring in patients with juvenile idiopathic arthritis to advance value-based care

  2025cites this paper
• Literature analysis and implication of biologic therapy for children with non-systemic juvenile idiopathic arthritis in real-world settings.

  2025cites this paper
• Effect of time to start of biologic therapy on treatment response in childhood arthritis: Results from the UCAN CAN-DU study.

  2025cites this paper
• Real-world use of biologics for systemic juvenile idiopathic arthritis: information from a Japanese hospital claims database.

  2025cites this paper
• The 2025 British Society for Rheumatology guideline for the prescription and monitoring of conventional synthetic disease-modifying anti-rheumatic drugs.

  2025cites this paper
• Can hydroxychloroquine and azithromycin combination cause cardiac rhythm disturbances in children with COVID-19 pneumonia?

  2025cites this paper
• The impact of BMI on disease activity and growth outcomes in juvenile idiopathic arthritis

  2025cites this paper
• Treatment of polyarticular juvenile idiopathic arthritis in Latin America: recommendations from the Pan-American League of Associations for Rheumatology.

  2025cites this paper
• Reply

  2024cites this paper
• Rhumatismes inflammatoires de l’enfant

  2024cites this paper
• Intra-articular corticosteroid utilization and characterizations of use in juvenile idiopathic arthritis within the PR-COIN registry

  2024cites this paper
• Atlantoaxial arthritis is more common in polyarticular JIA as compared to systemic onset JIA—Retrospective study

  2024cites this paper
• Magnetic resonance imaging of the musculoskeletal system in the diagnosis of rheumatic diseases in the pediatric population

  2024cites this paper
• Exploring Pain Adaptation in Youth With Juvenile Idiopathic Arthritis: Identifying Youth and Parent Resilience Resources and Mechanisms

  2024cites this paper
• Diagnostic accuracy of serum calprotectin measured by CLIA and EIA in juvenile idiopathic arthritis: a proof-of-concept study

  2024cites this paper
• Methotrexate for juvenile idiopathic arthritis.

  2024cites this paper
• Tofacitinib pharmacokinetics in children and adolescents with juvenile idiopathic arthritis

  2024cites this paper
• Three‐ and five‐year outcomes of an inception cohort of Australian children with juvenile idiopathic arthritis

  2024cites this paper
• Artropatías inflamatorias del niño

  2024cites this paper
• Electronic health record modification and dashboard development to improve clinical care in pediatric rheumatology

  2024cites this paper
• Juvenile Idiopathic Arthritis

  2024influential citation
• Comparative Effectiveness of a Second Tumor Necrosis Factor Inhibitor Versus a Non–Tumor Necrosis Factor Biologic in the Treatment of Patients With Polyarticular‐Course Juvenile Idiopathic Arthritis

  2024cites this paper
• Association of the MTHFR Gene Polymorphisms with Efficacy and Toxicity of Methotrexate in Patients with Juvenile Idiopathic Arthritis

  2024cites this paper
• Evolution of treatment options for juvenile idiopathic arthritis

  2024cites this paper
• When should the use of biological agents be considered in persistent oligoarticular juvenile idiopathic arthritis patients?

  2024cites this paper
• Impact of Musculoskeletal Pain on Functioning and Disability in Children with Juvenile Idiopathic Arthritis in Iceland

  2024cites this paper
• Trends in New Use of Disease‐Modifying Antirheumatic Drugs for Juvenile Idiopathic Arthritis Among Commercially Insured Children in the United States from 2001 to 2022

  2024cites this paper
• Application of genetically engineered biopharmaceutical products in children with various JIA forms in the Karaganda region

  2024cites this paper
• Ultrasonography of the pediatric elbow

  2023cites this paper
• Outcomes of intraarticular triamcinolone acetonide injection in children with non-systemic juvenile idiopathic arthritis

  2023cites this paper
• Imaging of juvenile spinal disorders.

  2023cites this paper
• Why and How Should We Assess the Cardiovascular Risk in Patients with Juvenile Idiopathic Arthritis? A Single-Centre Experience with Carotid Intima-Media Measurements

  2023cites this paper
• Etanercept for patients with juvenile idiopathic arthritis: drug levels and influence of concomitant methotrexate: observational study

  2023cites this paper
• The effect of TNF treatment uptake on incident hospital admission in Western Australia

  2023cites this paper
• Evaluating the Diagnostic Performance of Systemic Immune-Inflammation Index in Childhood Inflammatory Arthritis: A Focus on Differentiating Juvenile Idiopathic Arthritis from Reactive Arthritis

  2023cites this paper
• The dual role of body mass index on Juvenile Idiopathic Arthritis course: a pediatric experience

  2023influential citation
• What is causing this child's fever and knee pain?

  2023cites this paper
• Keluhan Muskuloskeletal Ektremitas atas Berdasarkan Metode Rapid Upper Limb Assessment (RULA) pada Pekerja Bagian Produksi Pt Panca Karya Unggul Abadi (PKUA)

  2023cites this paper
• Biologic switching patterns among children with non-systemic juvenile idiopathic arthritis

  2023cites this paper
• Monoarticular juvenile idiopathic arthritis as a distinct clinical entity A proof-of-concept study

  2023cites this paper
• Total Knee Arthroplasty In Patients With Juvenile Idiopathic Arthritis

  2023cites this paper
• Methotrexate for inflammatory skin disease in pediatric patients: Consensus treatment guidelines

  2023cites this paper
• How common is remission in rheumatoid factor-positive juvenile idiopathic arthritis patients? The multicenter Pediatric Rheumatology Academy (PeRA) research group experience

  2023cites this paper
• Ten-year safety and clinical benefit from open-label etanercept treatment in children and young adults with juvenile idiopathic arthritis.

  2023cites this paper
• MRI and CT findings of compressive cervical myelopathy in a dog with suspected immune‐mediated polyarthritis presenting with tetraparesis

  2023cites this paper
• Inflammatory Arthritis in a 19-month-old with Von Hippel-Lindau Disease.

  2023cites this paper
• Juvenile Idiopathic Arthritis (JIA) Transitional Care Systems Require Revision to Improve Patient Outcomes: Opinion Review

  2023cites this paper
• Inflammatory Bowel Disease as a Paradoxical Reaction to Anti-TNF-α Treatment—A Review

  2023cites this paper
• The Juvenile Spondyloarthritis Disease Activity Index Is a Useful Tool in Enthesitis-Related Arthritis

  2023cites this paper
• The feasibility of existing JADAS10 cut-off values in clinical practice: a study of data from The Finnish Rheumatology Quality Register

  2023cites this paper
• A comprehensive overview of juvenile idiopathic arthritis: From pathophysiology to management.

  2023cites this paper
• Predictors of relapse in patients with oligoarticular juvenile idiopathic arthritis in remission off medication

  2023cites this paper
• Biological Agent Switching in Patients With Juvenile Idiopathic Arthritis

  2023cites this paper
• The efficacy and safety of intra-articular injection of triamcinolone acetonide versus triamcinolone hexacetonide for treatment of juvenile idiopathic arthritis

  2022cites this paper
• 2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Oligoarthritis, Temporomandibular Joint Arthritis, and Systemic Juvenile Idiopathic Arthritis

  2022cites this paper
• 2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Recommendations for Nonpharmacologic Therapies, Medication Monitoring, Immunizations, and Imaging

  2022cites this paper
• Changing Patterns in Treatment, Remission Status, and Categories in a Long‐Term Nordic Cohort Study of Juvenile Idiopathic Arthritis

  2022cites this paper
• Assesment of Damage in Juvenile Idiopathic Arthritis: Single Center Experience

  2022cites this paper
• Juvenile idiopathic arthritis

  2022cites this paper
• Spondyloarthritiden im Kindes- und Erwachsenenalter

  2022cites this paper
• 2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Recommendations for Nonpharmacologic Therapies, Medication Monitoring, Immunizations, and Imaging

  2022cites this paper
• Implementation Science in Pediatric Rheumatology: A Path to Health Equity.

  2022cites this paper
• Intraarticular steroids as DMARD-sparing agents for juvenile idiopathic arthritis flares: Analysis of the Childhood Arthritis and Rheumatology Research Alliance Registry

  2022cites this paper
• Risk stratification using anti-citrullinated peptide antibodies (ACPA) in polyarticular subtypes of juvenile idiopathic arthritis in adulthood.

  2022cites this paper
• Serum Level of Calprotectin in Juvenile Idiopathic Arthritis and Its Correlation with Disease Activity Clinicaland Ultrasonographic

  2022cites this paper
• Uric acid could be a marker of cardiometabolic risk and disease severity in children with juvenile idiopathic arthritis

  2022cites this paper
• Long-term Efficacy and Safety of Canakinumab in the Treatment of Systemic Juvenile Idiopathic Arthritis in Japanese Patients: Results from an Open-label Phase III Study.

  2022cites this paper
• Disease Activity States of Juvenile Idiopathic Arthritis in a Referral Centre in Bangladesh

  2022cites this paper
• Perspectives on the use of non-biological pharmacotherapy for adult-onset Still’s disease

  2022cites this paper
• Effect of educational brochure compared with video on disease-related knowledge in patients with juvenile idiopathic arthritis: A randomized controlled trial

  2022cites this paper
• Foot and Ankle Conventional Radiography in Juvenile Idiopathic Arthritis: Does It Still Matter?

  2022cites this paper
• Spondyloarthritiden im Kindes- und Erwachsenenalter

  2022cites this paper
• Métricas em reumatologia pediátrica

  2022cites this paper
• Development of Inflammatory Bowel Disease in Children With Juvenile Idiopathic Arthritis Treated With Biologics

  2022cites this paper